Cutting Edge MarinBio Science Newsletter
July 23, 2026
Looking for a partner with 30 years of proven expertise in taking drugs from development to validation and
FDA approval?
Contact us @ 415.883.8000
BACKGROUND Over a million people across the world have follicular lymphoma. Lymphoma is a type of blood cancer where a subset of white blood
INTRODUCTION Adeno-Associated Virus (AAV) mediated gene therapy is rapidly advancing as new clinidal trials are beginning for the treatment of multiple diseases. As a
In a recent article published in Molecular Therapy, researchers from Voyage Therapeutics reported the development of a novel adeno-associated virus (AAV) capsid capable of
The U.S. Food and Drug Administration (FDA) is spearheading a transformative shift in preclinical drug safety testing through a comprehensive roadmap aimed at reducing and
SNIPRs, a Powerful New Therapeutic Approach A new technology has been developed that has the potential to accelerate cures for cancer and autoimmune diseases. Synthetic
Introduction More than 35 million people in the United States have Type 2 Diabetes (T2D), and approximately 100,000 of them die from T2D each year,
Introduction Two unsung hero hormones—Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have emerged as targets for groundbreaking therapies that reshape the way we approach
The MLR has been a mainstay for immunological drug discovery for decades, with a wide range of read-out assays such as cell proliferation and cytokine
The development and regulatory approval of pharmaceuticals represents one of the most rigorous scientific and administrative processes in modern healthcare. This comprehensive analysis explores the
A recent study published in the journal Cell unveils the discovery of vitamin C’s ability to directly modify proteins through a process known as
Summary Cancer cells avoid being killed by using immune evasion, allowing tumor cells to grow unchecked in cancer patients Immune evasion is a strategy
Targeted Protein Degradation in Clinical Trials: The Promise of PROTACs and Molecular Glues Targeted protein degradation (TPD) has emerged as a promising therapeutic approach, with
BACKGROUND Over a million people across the world have follicular lymphoma. Lymphoma is a type of blood cancer where a subset of white blood
In a recent study reported in the journal Molecular Therapy, a team led by researchers from the University of Science and Technology of China,
A groundbreaking study published in Nature by researchers from the Children’s Mercy Research Institute (Kansas) and the University of Kansas Medical Center introduces patient-derived organoid
Summary Getting therapeutic drugs into the brain is a huge problem. Most drugs cannot get into the brain, making it incredibly difficult to develop
Glioblastoma, an aggressive and terminal form of brain cancer Glioblastoma is a deadly form of cancer with a poor prognosis and no effective therapy. The
Antibody-conjugated lipid nanoparticles (LNPs) represent a transformative advancement in targeted drug delivery, combining the specificity of monoclonal antibodies with the versatility of LNPs. These systems
Introduction Degrader Antibody Conjugates (DACs) represent a revolutionary therapeutic modality that combines the precision of monoclonal antibodies (mAbs) with the potent protein degradation capabilities of
Dr. M. Arthur Charles, M.D., Ph.D Prediabetes can make you sick Prediabetes is a pandemic, with over 100 million (1 in 3)
With 30+ years of expertise in cell-based potency assay development, we provide accurate, GMP-compliant assays for AAV vectors and gene therapy candidates, ensuring a faster
Press Release | Marin Biologic Labs Achieves Flawless FDA Inspection for Second Consecutive Year, Expands Biopharmaceutical Services What are PROTACs? Proteolysis Targeting Chimeric (PROTAC) drugs
With over 30 years of expertise in cell-based potency assay development, we deliver precise, GMP-compliant potency assays for PROTACs, molecular glues, and other TPD drug
Gene therapy using adeno-associated virus (AAV) vectors offers a transformative approach for treating Duchenne muscular dystrophy (DMD), a genetic disorder caused by dystrophin deficiency. Achieving
Adeno-associated virus (AAV) vectors are highly regarded for their ability to deliver therapeutic genes effectively, with several approved therapies validating their clinical utility. Despite this,
RNA-based therapeutics have emerged as a promising method in modern medicine, offering potential treatments for a wide range of diseases (1). However, their effectiveness has
With over 30 years of expertise, we specialize in providing assay services essential for targeted protein degradation (TPD) drug development, preclinical studies, IND/BLA applications, and
What is a Cell Based Assay? A cell based assay uses live cells to quantify biological processes and evaluate cellular responses to various stimuli. These
FDA Approves First Engineered T-Cell Gene Therapy for Solid Tumor What is T Cell Gene Therapy? T cell gene therapy represents a revolutionary
In the ongoing fight against cancer, new and innovative cell-based therapies continually emerge, offering hope and progress where traditional treatments may fall short. Among these